Risk of bronchioloalveolar carcinoma in patients with human T-cell lymphotropic virus type 1 (HTLV-I): Case-control study results

Hiroaki Nomori, Takeshi Mori, Kenichi Iyama, Tatsuya Okamoto, Mitsuhiro Kamakura

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Human T-cell lymphotropic virus type 1 (HTLV-I) causes not only adult T-cell leukemia (ATL) but also HTLV-I associated T-cell bronchioloalveolitis, which is often chronic and subclinical. We have experienced eight HTVL-I carriers with bronchioloalveolar carcinoma, which is known to arise from bronchioloalveolar pneumocytes. This case-control study clarified the risk of bronchioloalveolar carcinoma in HTLV-I carriers. Materials and Methods: During the past four years, 212 lung cancer patients were examined for serum anti-HTLV-I antibody. They underwent surgical treatment for lung cancer at Kumamoto University Hospital. Of these, 8 (4%) were HTLV-I carriers. As controls for this case-control study, we selected 24 HTLV-I negative-lung cancer patients (1:3 case-control ratio) matched for sex, age, and smoking status. The distributions of histological types of lung cancer were compared between the case (HTLV-I positive) and control (HTLV-I negative) groups. Results: Histological types of the 8 HTLV-I carriers were bronchioloalveolar carcinoma in 6 patients and adenocarcinoma with bronchioloalveolar carcinoma component in 2. The prevalence of bronchioloalveolar carcinoma in HTLV-I carriers, 6 of 8 (75%), was significantly higher than the 6 of 24 (25%) in HTLV-I negative patients (p=0.02). The prevalence of bronchioloalveolar carcinoma or adenocarcinoma with bronchioloalveolar carcinoma component in HTLV-I carriers, 8 of 8 (100%), was also significantly higher than the 13 of 24 (54%) in HTLV-I negative patients (p=0.02). Conclusion: HTLV-I might be one risk of bronchioloalveolar carcinoma, probably because of inflammatory and/or immunologic responses involving bronchioloalveolar pneumocytes.

Original languageEnglish
Pages (from-to)19-23
Number of pages5
JournalAnnals of Thoracic and Cardiovascular Surgery
Volume17
Issue number1
Publication statusPublished - 2011 Feb

Fingerprint

Bronchiolo-Alveolar Adenocarcinoma
Human T-lymphotropic virus 1
Case-Control Studies
T-Lymphocytes
Lung Neoplasms
Alveolar Epithelial Cells
Adenocarcinoma
Adult T Cell Leukemia Lymphoma
Sex Ratio

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine
  • Gastroenterology

Cite this

Risk of bronchioloalveolar carcinoma in patients with human T-cell lymphotropic virus type 1 (HTLV-I) : Case-control study results. / Nomori, Hiroaki; Mori, Takeshi; Iyama, Kenichi; Okamoto, Tatsuya; Kamakura, Mitsuhiro.

In: Annals of Thoracic and Cardiovascular Surgery, Vol. 17, No. 1, 02.2011, p. 19-23.

Research output: Contribution to journalArticle

Nomori, Hiroaki ; Mori, Takeshi ; Iyama, Kenichi ; Okamoto, Tatsuya ; Kamakura, Mitsuhiro. / Risk of bronchioloalveolar carcinoma in patients with human T-cell lymphotropic virus type 1 (HTLV-I) : Case-control study results. In: Annals of Thoracic and Cardiovascular Surgery. 2011 ; Vol. 17, No. 1. pp. 19-23.
@article{9ce061e6b71740eeb965d3d607225c97,
title = "Risk of bronchioloalveolar carcinoma in patients with human T-cell lymphotropic virus type 1 (HTLV-I): Case-control study results",
abstract = "Background: Human T-cell lymphotropic virus type 1 (HTLV-I) causes not only adult T-cell leukemia (ATL) but also HTLV-I associated T-cell bronchioloalveolitis, which is often chronic and subclinical. We have experienced eight HTVL-I carriers with bronchioloalveolar carcinoma, which is known to arise from bronchioloalveolar pneumocytes. This case-control study clarified the risk of bronchioloalveolar carcinoma in HTLV-I carriers. Materials and Methods: During the past four years, 212 lung cancer patients were examined for serum anti-HTLV-I antibody. They underwent surgical treatment for lung cancer at Kumamoto University Hospital. Of these, 8 (4{\%}) were HTLV-I carriers. As controls for this case-control study, we selected 24 HTLV-I negative-lung cancer patients (1:3 case-control ratio) matched for sex, age, and smoking status. The distributions of histological types of lung cancer were compared between the case (HTLV-I positive) and control (HTLV-I negative) groups. Results: Histological types of the 8 HTLV-I carriers were bronchioloalveolar carcinoma in 6 patients and adenocarcinoma with bronchioloalveolar carcinoma component in 2. The prevalence of bronchioloalveolar carcinoma in HTLV-I carriers, 6 of 8 (75{\%}), was significantly higher than the 6 of 24 (25{\%}) in HTLV-I negative patients (p=0.02). The prevalence of bronchioloalveolar carcinoma or adenocarcinoma with bronchioloalveolar carcinoma component in HTLV-I carriers, 8 of 8 (100{\%}), was also significantly higher than the 13 of 24 (54{\%}) in HTLV-I negative patients (p=0.02). Conclusion: HTLV-I might be one risk of bronchioloalveolar carcinoma, probably because of inflammatory and/or immunologic responses involving bronchioloalveolar pneumocytes.",
author = "Hiroaki Nomori and Takeshi Mori and Kenichi Iyama and Tatsuya Okamoto and Mitsuhiro Kamakura",
year = "2011",
month = "2",
language = "English",
volume = "17",
pages = "19--23",
journal = "Annals of Thoracic and Cardiovascular Surgery",
issn = "1341-1098",
publisher = "Japanese Association for Coronary Artery Surgery",
number = "1",

}

TY - JOUR

T1 - Risk of bronchioloalveolar carcinoma in patients with human T-cell lymphotropic virus type 1 (HTLV-I)

T2 - Case-control study results

AU - Nomori, Hiroaki

AU - Mori, Takeshi

AU - Iyama, Kenichi

AU - Okamoto, Tatsuya

AU - Kamakura, Mitsuhiro

PY - 2011/2

Y1 - 2011/2

N2 - Background: Human T-cell lymphotropic virus type 1 (HTLV-I) causes not only adult T-cell leukemia (ATL) but also HTLV-I associated T-cell bronchioloalveolitis, which is often chronic and subclinical. We have experienced eight HTVL-I carriers with bronchioloalveolar carcinoma, which is known to arise from bronchioloalveolar pneumocytes. This case-control study clarified the risk of bronchioloalveolar carcinoma in HTLV-I carriers. Materials and Methods: During the past four years, 212 lung cancer patients were examined for serum anti-HTLV-I antibody. They underwent surgical treatment for lung cancer at Kumamoto University Hospital. Of these, 8 (4%) were HTLV-I carriers. As controls for this case-control study, we selected 24 HTLV-I negative-lung cancer patients (1:3 case-control ratio) matched for sex, age, and smoking status. The distributions of histological types of lung cancer were compared between the case (HTLV-I positive) and control (HTLV-I negative) groups. Results: Histological types of the 8 HTLV-I carriers were bronchioloalveolar carcinoma in 6 patients and adenocarcinoma with bronchioloalveolar carcinoma component in 2. The prevalence of bronchioloalveolar carcinoma in HTLV-I carriers, 6 of 8 (75%), was significantly higher than the 6 of 24 (25%) in HTLV-I negative patients (p=0.02). The prevalence of bronchioloalveolar carcinoma or adenocarcinoma with bronchioloalveolar carcinoma component in HTLV-I carriers, 8 of 8 (100%), was also significantly higher than the 13 of 24 (54%) in HTLV-I negative patients (p=0.02). Conclusion: HTLV-I might be one risk of bronchioloalveolar carcinoma, probably because of inflammatory and/or immunologic responses involving bronchioloalveolar pneumocytes.

AB - Background: Human T-cell lymphotropic virus type 1 (HTLV-I) causes not only adult T-cell leukemia (ATL) but also HTLV-I associated T-cell bronchioloalveolitis, which is often chronic and subclinical. We have experienced eight HTVL-I carriers with bronchioloalveolar carcinoma, which is known to arise from bronchioloalveolar pneumocytes. This case-control study clarified the risk of bronchioloalveolar carcinoma in HTLV-I carriers. Materials and Methods: During the past four years, 212 lung cancer patients were examined for serum anti-HTLV-I antibody. They underwent surgical treatment for lung cancer at Kumamoto University Hospital. Of these, 8 (4%) were HTLV-I carriers. As controls for this case-control study, we selected 24 HTLV-I negative-lung cancer patients (1:3 case-control ratio) matched for sex, age, and smoking status. The distributions of histological types of lung cancer were compared between the case (HTLV-I positive) and control (HTLV-I negative) groups. Results: Histological types of the 8 HTLV-I carriers were bronchioloalveolar carcinoma in 6 patients and adenocarcinoma with bronchioloalveolar carcinoma component in 2. The prevalence of bronchioloalveolar carcinoma in HTLV-I carriers, 6 of 8 (75%), was significantly higher than the 6 of 24 (25%) in HTLV-I negative patients (p=0.02). The prevalence of bronchioloalveolar carcinoma or adenocarcinoma with bronchioloalveolar carcinoma component in HTLV-I carriers, 8 of 8 (100%), was also significantly higher than the 13 of 24 (54%) in HTLV-I negative patients (p=0.02). Conclusion: HTLV-I might be one risk of bronchioloalveolar carcinoma, probably because of inflammatory and/or immunologic responses involving bronchioloalveolar pneumocytes.

UR - http://www.scopus.com/inward/record.url?scp=79955103394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955103394&partnerID=8YFLogxK

M3 - Article

C2 - 21587123

AN - SCOPUS:79955103394

VL - 17

SP - 19

EP - 23

JO - Annals of Thoracic and Cardiovascular Surgery

JF - Annals of Thoracic and Cardiovascular Surgery

SN - 1341-1098

IS - 1

ER -